Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.

[1]  C. Lacadie,et al.  Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating , 2022, NeuroImage: Clinical.

[2]  T. Kaptchuk,et al.  Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial. , 2022, JAMA pediatrics.

[3]  M. Grootenhuis,et al.  Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design , 2021, BMC Pediatrics.

[4]  Myles Jones,et al.  The efficacy of interactive group psychoeducation for children with leukaemia: A randomised controlled trial. , 2021, Patient education and counseling.

[5]  L. Schoonmade,et al.  Risk factors for steroid‐induced adverse psychological reactions and sleep problems in pediatric acute lymphoblastic leukemia: A systematic review , 2021, Psycho-oncology.

[6]  W. Chung,et al.  Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. , 2020, The lancet. Diabetes & endocrinology.

[7]  J. Coebergh,et al.  Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015 , 2020, Leukemia.

[8]  T. Oberlander,et al.  “Placebo by Proxy” and “Nocebo by Proxy” in Children: A Review of Parents' Role in Treatment Outcomes , 2020, Frontiers in Psychiatry.

[9]  A. Barsky,et al.  Placebo and Nocebo Effects. , 2020, The New England journal of medicine.

[10]  A. Moll,et al.  Determinants of health-related quality of life proxy rating disagreement between caregivers of children with cancer , 2019, Quality of Life Research.

[11]  H. Maurice‐Stam,et al.  Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) – parent form for children aged 2–18 years , 2018, Health and Quality of Life Outcomes.

[12]  Andrew L. Geers,et al.  Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus , 2018, Psychotherapy and Psychosomatics.

[13]  W. Tissing,et al.  Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Rief,et al.  Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice , 2015, Pharmacological Reviews.

[15]  E. R. Kloet,et al.  From Receptor Balance to Rational Glucocorticoid Therapy , 2014 .

[16]  L. Wedderburn,et al.  Mothers’ reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life , 2013, Pediatric Rheumatology.

[17]  A. Ni,et al.  Corticosteroids, Behavior, and Quality of Life in Children Treated for Acute Lymphoblastic Leukemia; A Multicentered Trial , 2012, Journal of pediatric hematology/oncology.

[18]  Luana Colloca,et al.  Nocebo effects, patient-clinician communication, and therapeutic outcomes. , 2012, JAMA.

[19]  T. Kaptchuk,et al.  Placebo by proxy , 2011, BMJ : British Medical Journal.

[20]  P. McGrath,et al.  Corticosteroids During Continuation Therapy for Acute Lymphoblastic Leukemia: The Psycho-social Impact , 2010, Issues in comprehensive pediatric nursing.

[21]  M. Relling,et al.  Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Wiedemann,et al.  Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. , 2008, European journal of pharmacology.

[23]  G. Geller,et al.  Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD. , 2007, Child: care, health and development.

[24]  F. Haour.  Mechanisms of the Placebo Effect and of Conditioning , 2005, Neuroimmunomodulation.

[25]  A. Pfeiffer,et al.  Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. , 2004, European journal of endocrinology.

[26]  R. Goodman,et al.  Dutch version of the Strengths and Difficulties Questionnaire (SDQ) , 2003, European Child & Adolescent Psychiatry.

[27]  J. Varni,et al.  The PedsQL™ in pediatric cancer , 2002, Cancer.

[28]  P. Mcgrath,et al.  'Enough is enough': qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia , 2002, Supportive Care in Cancer.

[29]  R. Goodman,et al.  Psychometric properties of the strengths and difficulties questionnaire. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  R. Sapolsky,et al.  How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. , 2000, Endocrine reviews.

[31]  R. Goodman.  The Strengths and Difficulties Questionnaire: a research note. , 1997, Journal of child psychology and psychiatry, and allied disciplines.

[32]  O. Bruni,et al.  The Sleep Disturbance Scale for Children (SDSC) Construct ion and validation of an instrument to evaluate sleep disturbances in childhood and adolescence , 1996, Journal of sleep research.

[33]  R. Ader,et al.  Classic conditioning and placebo effects in crossover studies , 1992, Clinical pharmacology and therapeutics.

[34]  U. Bingel,et al.  Nocebo Effects: Neurobiological Mechanisms and Strategies for Prevention and Optimizing Treatment. , 2018, International review of neurobiology.

[35]  L. Haverman,et al.  UvA-DARE ( Digital Academic Repository ) Electronic patient and parent reported outcomes in pediatric clinical practice , 2013 .

[36]  P. Muris,et al.  The Strengths and Difficulties Questionnaire (SDQ) , 2003, European Child & Adolescent Psychiatry.

[37]  A. Astrup,et al.  Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies , 2000, International Journal of Obesity.